Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival
FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer
Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints
Upper Endoscopy Most Effective When Performed in 3-Year Intervals
Women Who Concieve Using Fertility Drugs Have a Higher Risk Of Breast Cancer Than Non-Users
Variation in Breast Density May Be Strong Risk Factor
Study: Molecular Breast Imaging Can Be As Effective as MRI
Mammography Had Limited Impact Among Swedish Women Age 40-69
High Vitamin E Consumption Can Lower Liver Cancer Risks
Gene Expression Test Accurately Classifies “Inconclusive” Samples
CAP, ASCCP Recommendations Standardize Lesion Terminology
NCI-Approved CTEP Trials For The Month of July
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Trump targets HHS in $810M appropriations clawback
- Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?
